ArticleJournal of contemporary brachytherapy2017
Outcomes of salvage high-dose-rate brachytherapy with or without external beam radiotherapy for isolated vaginal recurrence of endometrial cancer.
Article in Journal of contemporary brachytherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.Virchows Archiv : an international journal of pathology · 2021Guideline
- Clinical outcomes of using 3D-printed applicators for high-dose-rate brachytherapy in gynecological malignancy.Journal of contemporary brachytherapy · 2024Article
- Clinical outcomes after salvage external beam radiotherapy combined with interstitial brachytherapy for locally advanced, recurrent endometrial cancer.Precision radiation oncology · 2023Article
- Review
- Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series.Journal of contemporary brachytherapy · 2021Article
- A single-institution review of image-guided brachytherapy for vaginal malignancies using customized molded applicators and interstitial needles.Journal of contemporary brachytherapy · 2021Article
- Transvaginal artificial ascites infusion as a spacer in gynecological brachytherapy: a novel technique.Journal of contemporary brachytherapy · 2020Article
- Image-guided interstitial brachytherapy boost for nasopharyngeal carcinoma: technical aspects.Journal of contemporary brachytherapy · 2020Article
- Prospective observational study on the safety of an original fiducial marker insertion for radiotherapy in gynecological cancer by a simple method.Journal of radiation research · 2019Observational
- Image-guided high-dose-rate interstitial brachytherapy for recurrent rectal cancer after salvage surgery: a case report.Journal of contemporary brachytherapy · 2019Article
- Usefulness of HE4 protein in differentiation of pelvic masses in woman.Przeglad menopauzalny = Menopause review · 2019Article
- Risk factors for fistula formation after interstitial brachytherapy for locally advanced gynecological cancers involving vagina.Journal of contemporary brachytherapy · 2018Article
- Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results.Journal of contemporary brachytherapy · 2018Review
- Combined external beam radiotherapy and vaginal brachytherapy versus vaginal brachytherapy in stage I, intermediate- and high-risk cases of endometrium carcinoma.Journal of contemporary brachytherapy · 2018Article
- Outcomes After Salvage Radiation Therapy for Recurrent Endometrial Cancer in Patients With No Prior Adjuvant Therapy: An Institutional Review.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study was designed to retrospectively analyze outcomes of high-dose-rate (HDR) brachytherapy, with or without external beam radiotherapy (EBRT), in patients with vaginal recurrence of endometrial carcinoma, and to identify factors prognostic of patient outcomes. MATERIAL AND
methodsThe medical records of all patients who underwent HDR brachytherapy for initial recurrence in the vagina of endometrial cancer after definitive surgery between 1992 and 2014 were retrospectively reviewed. All patients underwent either intracavitary brachytherapy (ICBT) or interstitial brachytherapy (ISBT) with or without EBRT. Late toxicity was graded using the EORTC (LENT/SOMA) scale, revised in 1995.
resultsThirty-seven patients were identified. The median follow-up time was 48 months (range: 6-225 months). Of these 37 patients, 23 underwent ICBT, 14 underwent ISBT, and 26 underwent EBRT. Tumor size at first examination of initial relapse was significantly larger in the ISBT than in the ICBT group. The 4-year respective overall survival (OS), local control (LC), and progression-free survival (PFS) rates in the entire cohort were 81.0%, 77.9%, and 56.8%, respectively. The interval between diagnosis of first recurrence and radiotherapy (< 3 months, ≥ 3 months) was a significant predictor of LC and PFS. OS and LC rates did not differ significantly in the ICBT and ISBT groups. Two patients experienced grade 2 rectal bleeding, and four experienced grade 2 hematuria. No grade 3 or higher late complications were observed.
conclusionsSalvage HDR brachytherapy is an optimal for treating vaginal recurrence of endometrial carcinoma with acceptable morbidity. Early radiotherapy, including brachytherapy, should be considered for women who experience vaginal recurrence of endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.